Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00872196 · ClinicalTrials.gov registry record · Phase 2
A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies
A Phase 2 study of Hepatitis C Virus Infection, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT00872196 is a Phase 2 study of Hepatitis C Virus Infection that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 5 participants, below the 201-participant average among 5 other Hepatitis C Virus Infection trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00872196, a Phase 2 study of Hepatitis C Virus Infection, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a follow-up study with no treatment and only samples being collected.
Conditions Studied
Interventions
- DRUG ABT-072
Study Locations (1)
California
- Site Reference ID/Investigator# 18222 - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00872196
The ClinicalTrials.gov registry entry for NCT00872196 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 5 other Hepatitis C Virus Infection trials with a reported enrollment target (98% lower). The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis C Virus Infection appearing as the primary indexed condition, and to 1 intervention - of which ABT-072 is the first listed.
NCT00872196 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00872196 about?
NCT00872196 is a clinical study titled "A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies". This is a follow-up study with no treatment and only samples being collected.
What is the current status of trial NCT00872196?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2009-04. Estimated completion is 2010-04.
What conditions does trial NCT00872196 study?
This clinical trial studies the following conditions: Hepatitis C Virus Infection.
What interventions are being tested in trial NCT00872196?
The interventions under investigation include: ABT-072 (DRUG).
Who is sponsoring clinical trial NCT00872196?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00872196 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C Virus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection
COMPLETED · Phase 2
-
Hepatitis C Tracker Study
RECRUITING · NA
-
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
COMPLETED · Phase 3
-
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection
COMPLETED · Phase 3
-
Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.